Person · CIK 1742485

Neil Kumar

Chief Executive Officer at BridgeBio Pharma; director at BridgeBio Oncology Therapeutics and Maze Therapeutics

Earlier: LianBio and Eidos Therapeutics

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$151.1M

Noticed on Form 144$116M

Bought on Form 4$116.2M

Companies5

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
BridgeBio Pharma BBIO	Common Stock	Directly	243,327	Sep 17, 2026 · Filing · EDGAR
BridgeBio Pharma BBIO	Common Stock	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	3,568,447	Sep 17, 2026 · Filing · EDGAR
BridgeBio Pharma BBIO	Common Stock	See Footnote	995,686	Nov 16, 2023 · Filing · EDGAR
BridgeBio Pharma BBIO	Common Stock	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)	995,686	Feb 16, 2025 · Filing · EDGAR
BridgeBio Pharma BBIO	Common Stock	By NK 2026 GRAT	750,000	Sep 17, 2026 · Filing · EDGAR
BridgeBio Pharma BBIO	Common Stock	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	495,686	Sep 17, 2026 · Filing · EDGAR
BridgeBio Pharma BBIO	Restricted Stock Units into Common Stock	Directly	117,596	Aug 16, 2026 · Filing · EDGAR
BridgeBio Pharma BBIO	Restricted Stock Units into Common Stock	Directly	115,538	Aug 16, 2026 · Filing · EDGAR
BridgeBio Pharma BBIO	Restricted Stock Units into Common Stock	Directly	91,274	Aug 16, 2026 · Filing · EDGAR
BridgeBio Pharma BBIO	Restricted Stock Units into Common Stock	Directly	67,088	Aug 16, 2026 · Filing · EDGAR
BridgeBio Oncology Therapeutics BBOT	Stock Option (Right to Buy) exercise $7.73, expires Jun 15, 2036, into Common Stock	Directly	31,675	Jun 16, 2026 · Filing · EDGAR
Maze Therapeutics MAZE	Stock Option (Right to Buy) exercise $30.38, expires Mar 26, 2036, into Common Stock	Directly	33,417	Mar 27, 2026 · Filing · EDGAR
LianBio	Ordinary Shares	By BridgeBio Pharma LLC	5,002,792	Oct 29, 2021 · Filing · EDGAR
Eidos Therapeutics	Common Stock	See Footnote	24,575,501	Jul 3, 2019 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)	Bought (Form 4)
Q3 2026	$4.4M	$5.3M	—
Q2 2026	$18.6M	$10.7M	—
Q1 2026	$19.3M	$27.9M	—
Q4 2025	$19.2M	$17M	—
Q3 2025	$12.5M	$11.6M	—
Q2 2025	$5.9M	$885K	—
Q1 2025	$28.2M	$34M	—
Q4 2024	$614K	$612K	—
Q3 2024	$676K	$668K	—
Q4 2023	$1.5M	$1.5M	—
Q3 2023	$1.5M	$1.5M	—
Q2 2023	$4.3M	$4.3M	—
Q1 2023	$4.1M	Not machine-readable	—
Q4 2022	$2M	Not machine-readable	—
Q3 2020	$6.6M	Not machine-readable	—
Q2 2020	$9.7M	Not machine-readable	—
Q1 2020	$11.9M	Not machine-readable	—
Q3 2019	—	—	$26.4M
Q2 2019	—	—	$28.6M
Q4 2018	—	—	$44.2M
Q2 2018	—	—	$17M

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
BridgeBio Pharma BBIO · Morgan Stanley Smith Barney · 10b5-1 plan adopted May 13, 2026 · 2 notices
Aug 19, 2026	30,000 · ~$2.5M	Aug 19, 2026	Partly sold Sold 16,821 in 2 sales, Aug 19 to Sep 17 · $1.3M likely match Form 4 (1) · Form 4 (2)	Filing · EDGAR
Aug 18, 2026	34,980 · ~$2.8M	Aug 18, 2026	Partly sold Sold 33,160 in 3 sales, Aug 18 to Sep 17 · $2.7M likely match Form 4 (1) · Form 4 (2)	Filing · EDGAR
BridgeBio Pharma BBIO · Morgan Stanley Smith Barney · 10b5-1 plan adopted Mar 31, 2025 · 13 notices
May 21, 2026	26,103 · ~$1.8M	May 21, 2026	Partly sold Sold 24,999 in 7 sales, Jun 5 to Aug 19 · $1.8M likely match Form 4 (1) · Form 4 (2)	Filing · EDGAR
Apr 9, 2026	120,000 · ~$8.9M	Apr 9, 2026	Partly sold Sold 116,870 in 18 sales, May 8 to Jun 5 · $7.9M likely match Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
Mar 13, 2026	140,000 · ~$9.5M	Mar 13, 2026	Sold as noticed Sold 141,134 in 17 sales, Mar 13 to May 21 · $10.1M Form 4 (1) · Form 4 (2) · Form 4 (3) · Form 4 (4)	Filing · EDGAR
Feb 19, 2026	28,053 · ~$2.1M	Feb 19, 2026	Sold as noticed Sold 28,099 in 5 sales, Mar 13 to May 7 · $2M likely match Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
Jan 8, 2026	120,000 · ~$8.9M	Jan 8, 2026	Sold as noticed Sold 120,891 in 15 sales, Feb 10 to Mar 12 · $8.5M likely match Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
Jan 8, 2026	100,000 · ~$7.4M	Jan 8, 2026	Sold as noticed Sold 100,680 in 14 sales, Jan 8 to Mar 12 · $7.5M Form 4 (1) · Form 4 (2) · Form 4 (3) · Form 4 (4)	Filing · EDGAR
Dec 15, 2025	30,011 · ~$2.3M	Dec 15, 2025	Sold as noticed Sold 30,166 in 2 sales, Dec 15 to Jan 9 · $2.3M Form 4 (1) · Form 4 (2)	Filing · EDGAR
Nov 20, 2025	26,156 · ~$1.7M	Nov 20, 2025	Partly sold Sold 24,627 in 7 sales, Dec 5 to Jan 9 · $1.8M likely match Form 4 (1) · Form 4 (2)	Filing · EDGAR
Oct 8, 2025	120,000 · ~$6.5M	Oct 8, 2025	Partly sold Sold 118,028 in 14 sales, Nov 7 to Dec 15 · $8.1M likely match Form 4 (1) · Form 4 (2) · Form 4 (3) · Form 4 (4)	Filing · EDGAR
Oct 8, 2025	120,000 · ~$6.5M	Oct 8, 2025	Sold as noticed Sold 120,502 in 11 sales, Oct 8 to Dec 4 · $7M Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
Aug 20, 2025	26,156 · ~$1.3M	Aug 20, 2025	Sold as noticed Sold 26,226 in 6 sales, Sep 5 to Nov 7 · $1.4M likely match Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
Jul 1, 2025	120,000 · ~$5.2M	Jul 1, 2025	Partly sold Sold 106,528 in 11 sales, Aug 8 to Sep 5 · $5.3M likely match Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
Jul 1, 2025	120,000 · ~$5.2M	Jul 1, 2025	Sold as noticed Sold 121,128 in 11 sales, Jul 1 to Sep 5 · $5.4M Form 4 (1) · Form 4 (2) · Form 4 (3) · Form 4 (4)	Filing · EDGAR
BridgeBio Pharma BBIO · Morgan Stanley Smith Barney · 10b5-1 plan adopted Mar 22, 2024 · 6 notices
May 19, 2025	26,156 · ~$885K	May 19, 2025	Partly sold Sold 21,600 in 3 sales, Jul 1 to Jul 1 · $919K likely match Form 4	Filing · EDGAR
Feb 25, 2025	300,000 · ~$10.9M	Feb 25, 2025	Partly sold Sold 251,156 in 6 sales, Feb 25 to May 19 · $8.7M likely match Form 4 (1) · Form 4 (2) · Form 4 (3) · Form 4 (4)	Filing · EDGAR
Feb 19, 2025	31,543 · ~$1.1M	Feb 19, 2025	Sold as noticed Sold 31,467 at $36.14 on Feb 19 · $1.1M Form 4	Filing · EDGAR
Jan 28, 2025	600,000 · ~$22M	Jan 28, 2025	Sold as noticed Sold 600,076 in 4 sales, Jan 28 to Feb 19 · $21.8M Form 4 (1) · Form 4 (2)	Filing · EDGAR
Nov 19, 2024	27,389 · ~$612K	Nov 19, 2024	Sold as noticed Sold 27,389 in 2 sales, Nov 19 to Nov 19 · $614K Form 4	Filing · EDGAR
Aug 19, 2024	27,389 · ~$668K	Aug 19, 2024	Sold as noticed Sold 27,389 in 2 sales, Aug 19 to Aug 19 · $676K Form 4	Filing · EDGAR
BridgeBio Pharma BBIO · Morgan Stanley Smith Barney · 10b5-1 plan adopted Dec 5, 2022 · 5 notices
Nov 17, 2023	51,552 · ~$1.5M	Nov 17, 2023	Sold as noticed Sold 51,552 in 2 sales, Nov 17 to Nov 17 · $1.5M Form 4	Filing · EDGAR
Aug 17, 2023	51,552 · ~$1.5M	Aug 17, 2023	Sold as noticed Sold 51,552 at $28.59 on Aug 17 · $1.5M Form 4	Filing · EDGAR
May 17, 2023	51,552 · ~$726K	May 17, 2023	Sold as noticed Sold 51,552 at $14.01 on May 17 · $722K Form 4	Filing · EDGAR
May 3, 2023	120,000 · ~$1.7M	May 3, 2023	Sold as noticed Sold 120,000 at $14.18 on May 3 · $1.7M Form 4	Filing · EDGAR
Apr 5, 2023	120,000 · ~$1.9M	Apr 5, 2023	Sold as noticed Sold 120,000 at $15.46 on Apr 5 · $1.9M Form 4	Filing · EDGAR
Sales without a matching Form 144 · 49 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice BridgeBio Pharma (BBIO): Sold 75,000 at $33.40 on May 20, 2025 · $2.5M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 120,000 at $10.96 on Mar 3, 2023 · $1.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 44,798 at $12.70 on Feb 17, 2023 · $569K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 120,000 at $11.01 on Feb 3, 2023 · $1.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 120,000 at $7.67 on Jan 5, 2023 · $921K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 200,000 at $8.26 on Dec 21, 2022 · $1.7M	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 34,640 at $9.40 on Nov 17, 2022 · $326K	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 6,759 at $27.36 on Aug 4, 2020 · $185K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 7,184 at $26.70 on Aug 4, 2020 · $192K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 3,040 at $28.12 on Aug 3, 2020 · $85K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 63,017 at $27.23 on Aug 3, 2020 · $1.7M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 56,445 at $30.22 on Jul 2, 2020 · $1.7M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 2,700 at $32.42 on Jul 1, 2020 · $88K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 33,700 at $31.67 on Jul 1, 2020 · $1.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 50,625 at $30.63 on Jul 1, 2020 · $1.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 10,600 at $30.01 on Jun 8, 2020 · $318K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 5,930 at $30.05 on Jun 3, 2020 · $178K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 8,709 at $29.71 on Jun 1, 2020 · $259K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 71,291 at $29.13 on Jun 1, 2020 · $2.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 34,834 at $31.23 on May 5, 2020 · $1.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 44,766 at $30.86 on May 5, 2020 · $1.4M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 33,974 at $29.77 on May 4, 2020 · $1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 5,706 at $29.13 on May 4, 2020 · $166K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 4,098 at $29.78 on May 1, 2020 · $122K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 36,622 at $29.06 on May 1, 2020 · $1.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 1,805 at $25.48 on Apr 7, 2020 · $46K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 100 at $25.10 on Apr 3, 2020 · $3K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 200 at $25.09 on Apr 3, 2020 · $5K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 15,778 at $25.04 on Apr 2, 2020 · $395K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 1,382 at $28.20 on Apr 1, 2020 · $39K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 12,976 at $27.45 on Apr 1, 2020 · $356K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 20,040 at $26.38 on Apr 1, 2020 · $529K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 27,719 at $25.52 on Apr 1, 2020 · $708K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 201 at $33.22 on Mar 3, 2020 · $7K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 12,090 at $32.60 on Mar 3, 2020 · $394K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 7,756 at $31.76 on Mar 3, 2020 · $246K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 995 at $33.33 on Mar 2, 2020 · $33K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 59,305 at $32.53 on Mar 2, 2020 · $1.9M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 39,653 at $31.88 on Mar 2, 2020 · $1.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 30,893 at $34.87 on Feb 5, 2020 · $1.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 54,951 at $34.55 on Feb 4, 2020 · $1.9M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 2,100 at $35.20 on Feb 3, 2020 · $74K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 32,056 at $34.92 on Feb 3, 2020 · $1.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 6,668 at $32.88 on Jan 3, 2020 · $219K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 77,271 at $32.14 on Jan 3, 2020 · $2.5M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 100 at $35.17 on Jan 2, 2020 · $4K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 5,077 at $34.19 on Jan 2, 2020 · $174K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 19,793 at $33.41 on Jan 2, 2020 · $661K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 11,091 at $32.55 on Jan 2, 2020 · $361K (10b5-1 plan)	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

BridgeBio Pharma BBIO Chief Executive Officer · filings 2019 to 2026 · sold $151.1M · $116M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 17, 2026	Sale under a 10b5-1 plan	−8,721	$69.01	$602K	496,965 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Sep 17, 2026	Sale under a 10b5-1 plan	−1,279	$69.57	$89K	495,686 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Aug 19, 2026	Sale under a 10b5-1 plan	−8,100	$83.86	$679K	507,586 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Aug 19, 2026	Sale under a 10b5-1 plan	−1,800	$84.69	$152K	505,786 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Aug 19, 2026	Sale under a 10b5-1 plan	−100	$85.65	$9K	505,686 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Aug 18, 2026	Sale under a 10b5-1 plan	−1,900	$81.15	$154K	276,407 direct	Filing · EDGAR
Aug 18, 2026	Sale under a 10b5-1 plan	−17,279	$82.21	$1.4M	259,128 direct	Filing · EDGAR
Aug 18, 2026	Sale under a 10b5-1 plan	−14,602	$82.99	$1.2M	244,526 direct	Filing · EDGAR
Aug 18, 2026	Sale under a 10b5-1 plan	−1,199	$83.77	$100K	243,327 direct	Filing · EDGAR
Aug 16, 2026	Option or RSU exercised or converted	+33,544			276,871 direct	Filing · EDGAR
Aug 16, 2026	Option or RSU exercised or converted	+19,599			296,470 direct	Filing · EDGAR
Aug 16, 2026	Option or RSU exercised or converted	+11,554			308,024 direct	Filing · EDGAR
Aug 16, 2026	Option or RSU exercised or converted	+6,520			314,544 direct	Filing · EDGAR
Aug 16, 2026	Shares withheld for tax or exercise price	−36,237	$79.86	$2.9M	278,307 direct	Filing · EDGAR
Aug 16, 2026	Option or RSU exercised or converted Restricted Stock Units	−33,544			67,088 direct	Filing · EDGAR
Aug 16, 2026	Option or RSU exercised or converted Restricted Stock Units	−19,599			117,596 direct	Filing · EDGAR
Aug 16, 2026	Option or RSU exercised or converted Restricted Stock Units	−11,554			115,538 direct	Filing · EDGAR
Aug 16, 2026	Option or RSU exercised or converted Restricted Stock Units	−6,520			91,274 direct	Filing · EDGAR
Jun 5, 2026	Sale under a 10b5-1 plan	−7,147	$67.20	$480K	528,539 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Jun 5, 2026	Sale under a 10b5-1 plan	−8,437	$67.88	$573K	520,102 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Jun 5, 2026	Sale under a 10b5-1 plan	−4,416	$68.96	$305K	515,686 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Jun 5, 2026	Sale under a 10b5-1 plan	−7,148	$67.20	$480K	4,331,299 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Jun 5, 2026	Sale under a 10b5-1 plan	−8,437	$67.88	$573K	4,322,862 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Jun 5, 2026	Sale under a 10b5-1 plan	−4,415	$68.96	$304K	4,318,447 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Jun 4, 2026	Sale under a 10b5-1 plan	−2,200	$65.72	$145K	553,486 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Jun 4, 2026	Sale under a 10b5-1 plan	−1,429	$66.72	$95K	552,057 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Jun 4, 2026	Sale under a 10b5-1 plan	−15,921	$67.74	$1.1M	536,136 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Jun 4, 2026	Sale under a 10b5-1 plan	−450	$68.27	$31K	535,686 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Jun 4, 2026	Sale under a 10b5-1 plan	−2,200	$65.72	$145K	4,356,247 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Jun 4, 2026	Sale under a 10b5-1 plan	−1,429	$66.72	$95K	4,354,818 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Jun 4, 2026	Sale under a 10b5-1 plan	−15,921	$67.74	$1.1M	4,338,897 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Jun 4, 2026	Sale under a 10b5-1 plan	−450	$68.27	$31K	4,338,447 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
May 21, 2026	Sale under a 10b5-1 plan	−2,256	$67.57	$152K	267,174 direct	Filing · EDGAR
May 21, 2026	Sale under a 10b5-1 plan	−6,725	$68.30	$459K	260,449 direct	Filing · EDGAR
May 21, 2026	Sale under a 10b5-1 plan	−5,072	$69.22	$351K	255,377 direct	Filing · EDGAR
May 21, 2026	Sale under a 10b5-1 plan	−11,250	$70.48	$793K	244,127 direct	Filing · EDGAR
May 21, 2026	Sale under a 10b5-1 plan	−800	$70.92	$57K	243,327 direct	Filing · EDGAR
May 16, 2026	Option or RSU exercised or converted	+33,544			267,995 direct	Filing · EDGAR
May 16, 2026	Option or RSU exercised or converted	+19,599			287,594 direct	Filing · EDGAR
May 16, 2026	Option or RSU exercised or converted	+11,553			299,147 direct	Filing · EDGAR
May 16, 2026	Option or RSU exercised or converted	+6,519			305,666 direct	Filing · EDGAR
May 16, 2026	Shares withheld for tax or exercise price	−36,236	$66.13	$2.4M	269,430 direct	Filing · EDGAR
May 16, 2026	Option or RSU exercised or converted Restricted Stock Units	−33,544			100,632 direct	Filing · EDGAR
May 16, 2026	Option or RSU exercised or converted Restricted Stock Units	−19,599			137,195 direct	Filing · EDGAR
May 16, 2026	Option or RSU exercised or converted Restricted Stock Units	−11,553			127,092 direct	Filing · EDGAR
May 16, 2026	Option or RSU exercised or converted Restricted Stock Units	−6,519			97,794 direct	Filing · EDGAR
May 8, 2026	Sale under a 10b5-1 plan	−13,973	$66.65	$931K	561,713 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
May 8, 2026	Sale under a 10b5-1 plan	−5,077	$67.35	$342K	556,636 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
May 8, 2026	Sale under a 10b5-1 plan	−950	$68.35	$65K	555,686 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
May 8, 2026	Sale under a 10b5-1 plan	−13,974	$66.65	$931K	4,364,473 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
May 8, 2026	Sale under a 10b5-1 plan	−5,076	$67.35	$342K	4,359,397 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
May 8, 2026	Sale under a 10b5-1 plan	−950	$68.35	$65K	4,358,447 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
May 7, 2026	Sale under a 10b5-1 plan	−11,217	$67.50	$757K	584,469 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
May 7, 2026	Sale under a 10b5-1 plan	−8,333	$68.38	$570K	576,136 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
May 7, 2026	Sale under a 10b5-1 plan	−450	$69.09	$31K	575,686 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
May 7, 2026	Sale under a 10b5-1 plan	−11,217	$67.49	$757K	4,387,230 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
May 7, 2026	Sale under a 10b5-1 plan	−8,334	$68.38	$570K	4,378,896 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
May 7, 2026	Sale under a 10b5-1 plan	−449	$69.09	$31K	4,378,447 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Apr 10, 2026	Sale under a 10b5-1 plan	−20,000	$74.60	$1.5M	595,686 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR
Apr 10, 2026	Sale under a 10b5-1 plan	−20,000	$74.60	$1.5M	4,398,447 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	Filing · EDGAR

327 earlier transactions are in the filing list below.

BridgeBio Oncology Therapeutics BBOT Director · filings 2025 to 2026

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 16, 2026	Grant or award from the company Stock Option (Right to Buy)	+31,675			31,675 direct	Filing · EDGAR

Maze Therapeutics MAZE Director · filings 2026 to 2026

Date	Transaction	Shares	Price	Value	Held after	Source
Mar 27, 2026	Grant or award from the company Stock Option (Right to Buy)	+33,417			33,417 direct	Filing · EDGAR

LianBio Director · filings 2021 to 2021

No transactions in the filings read; Form 144 notices are listed above.

Eidos Therapeutics Chief Executive Officer · filings 2018 to 2019 · bought $116.2M

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 3, 2019	Open-market or private purchase	+882,353	$29.90	$26.4M	24,575,501 See Footnote	Filing · EDGAR
May 24, 2019	Open-market or private purchase	+1,103,848	$25.93	$28.6M	23,693,148 See Footnote	Filing · EDGAR
Dec 10, 2018	Open-market or private purchase	+37,989	$13.29	$505K	22,586,636 See Footnote	Filing · EDGAR
Dec 10, 2018	Open-market or private purchase	+2,664	$13.96	$37K	22,589,300 See Footnote	Filing · EDGAR
Dec 7, 2018	Open-market or private purchase	+36,314	$13.94	$506K	22,543,787 See Footnote	Filing · EDGAR
Dec 7, 2018	Open-market or private purchase	+4,860	$14.36	$70K	22,548,647 See Footnote	Filing · EDGAR
Dec 6, 2018	Open-market or private purchase	+38,970	$13.34	$520K	22,507,473 See Footnote	Filing · EDGAR
Dec 5, 2018	Open-market or private purchase	+1,103,848	$14.01	$15.5M	22,468,503 See Footnote	Filing · EDGAR
Dec 3, 2018	Open-market or private purchase	+1,750,000	$15.50	$27.1M	21,364,655 See Footnote	Filing · EDGAR
Jun 22, 2018	Derivative converted	+18,826,417			18,826,417 See footnote	Filing · EDGAR
Jun 22, 2018	Shares withheld for tax or exercise price	−211,762	$17.00	$3.6M	18,614,655 See footnote	Filing · EDGAR
Jun 22, 2018	Open-market or private purchase	+1,000,000	$17.00	$17M	19,614,655 See footnote	Filing · EDGAR
Jun 22, 2018	In-the-money option exercised Warrants	−332,262			0 See footnote	Filing · EDGAR
Jun 22, 2018	In-the-money option exercised Series B Convertible Preferred Stock	+332,262			2,909,029 See footnote	Filing · EDGAR
Jun 22, 2018	Derivative converted Series B Convertible Preferred Stock	−2,909,029			0 See footnote	Filing · EDGAR
Jun 22, 2018	Derivative converted Series Seed Preferred Stock	−12,832,123			0 See footnote	Filing · EDGAR

All 120 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Sep 21, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 20, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 19, 2026	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 18, 2026	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 18, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jun 18, 2026	Form 4	BridgeBio Oncology Therapeutics BBOT	Filing · EDGAR
Jun 8, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
May 26, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
May 21, 2026	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
May 19, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
May 11, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Apr 13, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Apr 9, 2026	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Mar 31, 2026	Form 4	Maze Therapeutics MAZE	Filing · EDGAR
Mar 31, 2026	Form 3	Maze Therapeutics MAZE	Filing · EDGAR
Mar 19, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Mar 16, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Mar 13, 2026	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 23, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 19, 2026	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 18, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 12, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jan 12, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jan 8, 2026	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Jan 8, 2026	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Dec 16, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Dec 15, 2025	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Dec 8, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Nov 24, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Nov 20, 2025	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Nov 18, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Nov 10, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Oct 10, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Oct 8, 2025	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Oct 8, 2025	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Sep 8, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 22, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 20, 2025	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 19, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 18, 2025	Form 3	BridgeBio Oncology Therapeutics BBOT	Filing · EDGAR
Aug 11, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jul 3, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jul 1, 2025	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Jul 1, 2025	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
May 20, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
May 19, 2025	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Apr 24, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Mar 27, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Mar 21, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 27, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 25, 2025	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 19, 2025	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 19, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jan 30, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jan 28, 2025	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Dec 27, 2024	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Dec 12, 2024	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Nov 20, 2024	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Nov 19, 2024	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Nov 19, 2024	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 20, 2024	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 19, 2024	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
May 17, 2024	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Mar 14, 2024	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 21, 2024	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Nov 20, 2023	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Nov 17, 2023	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 18, 2023	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 17, 2023	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
May 18, 2023	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
May 17, 2023	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
May 5, 2023	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
May 3, 2023	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Apr 7, 2023	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Apr 5, 2023	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Mar 3, 2023	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 21, 2023	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 14, 2023	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 6, 2023	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jan 6, 2023	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Dec 21, 2022	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Nov 18, 2022	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 18, 2022	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
May 18, 2022	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Mar 18, 2022	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 18, 2022	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Dec 7, 2021	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Nov 18, 2021	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Nov 9, 2021	Form 3/A	LianBio	Filing · EDGAR
Oct 29, 2021	Form 3	LianBio	Filing · EDGAR
Aug 18, 2021	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
May 18, 2021	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 18, 2021	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 12, 2021	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 12, 2021	Form 5	BridgeBio Pharma BBIO	Filing · EDGAR
Nov 18, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 18, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 5, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jul 6, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jun 10, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jun 5, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jun 3, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
May 6, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
May 5, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Apr 9, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Apr 6, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Apr 3, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Mar 4, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 14, 2020	Form 5/A	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 13, 2020	Form 5	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 7, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 5, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jan 6, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jul 8, 2019	Form 4	Eidos Therapeutics	Filing · EDGAR
Jul 3, 2019	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jun 27, 2019	Form 3	BridgeBio Pharma BBIO	Filing · EDGAR
May 29, 2019	Form 4	Eidos Therapeutics	Filing · EDGAR
Feb 14, 2019	Form 5	Eidos Therapeutics	Filing · EDGAR
Jun 22, 2018	Form 4	Eidos Therapeutics	Filing · EDGAR
Jun 19, 2018	Form 3	Eidos Therapeutics	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 9:44 PM ET. The filing on SEC.gov is the record.